GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
The Pharma Letter2 天
New data for GSK’s Arexvy RSV vaccine
US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...
FiercePharma3 天
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
Business Wire3 天
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help ...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
来自MSN3 天
GSK’s Arexvy Vaccine Shows Promise for Broader Use
GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
Monthly Prescribing Reference2 天
Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine ...
Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...
生物谷5 天
葛兰素史克公布呼吸道合胞病毒（RSV）疫苗Arexvy积极数据，疫苗保护 ...
Arexvy是全球首款RSV疫苗，其获批基于在60岁及以上成人中的显著效力，包括因患有某些基础疾病的高风险人群。今日公布的结果显示，接种GSK单剂RSV疫苗在三个RSV完整流行季中的累积保护效力具有临床意义。与安慰剂相比，该疫苗对于RSV引发的下呼吸 ...
GSK reports preliminary data for AREXVY
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
3项关于RSV疫苗/药物最新数据公布，涉及辉瑞Abrysvo、GSK Arexvy......
近日，在洛杉矶举行的2024年美国感染性疾病周（IDWeek）会议期间，默沙东和辉瑞分别展示了其针对呼吸道合胞病毒（RSV）的预防药物新数据，并宣称这些药物对预防感染及相关住院具有强大的保护效果。IDWeek是全球感染病学领域的顶级学术盛会，每年吸引 ...
GSK报告年轻成年人Arexvy疫苗数据令人鼓舞
全球医疗保健公司GSK plc (LSE/NYSE: GSK)今天宣布了正在进行的临床试验的初步数据,这些数据表明其呼吸道合胞病毒(RSV)疫苗Arexvy可能对更广泛的成年人群有效。 目前,Arexvy已在50多个国家获准用于60岁及以上人群,在美国和欧洲获准用于50-59岁高风险人群。新数据可能将RSV保护范围扩大到18-49岁有基础疾病的成年人和免疫功能低下的成年人。 III期临床试验(NC ...